Tivicay Tablet, Film Coated
NDC Package 60760-748-07

11-digit billing NDC: 60760074807 · Billing unit: EA · 7 EA per package

Package Information

Tivicay (dolutegravir sodium) tablets is tIVICAY and TIVICAY PD are indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor [INSTI]-naïve) aged at least 4 weeks and weighing at least 3 kg [see Microbiology ( 12.4)]. This formulation utilizes a tablet, film coated delivery system. Marketed by St. Mary's Medical Park Pharmacy, this product is identified by NDC 60760-748 and is authorized under FDA application NDA204790.

Identification & Billing

NDC Package Code
60760-748-07
Package Description
7 TABLET, FILM COATED in 1 BOTTLE, PLASTIC
Product Code
11-Digit Billing Format
60760074807
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
7 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Tivicay
Non-Proprietary Name
Dolutegravir Sodium
Substance Name
Dolutegravir Sodium
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
TIVICAY and TIVICAY PD are indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor [INSTI]-naïve) aged at least 4 weeks and weighing at least 3 kg [see Microbiology ( 12.4)]. TIVICAY is indicated in combination with rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/ mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent.

Regulatory & Marketing

Labeler Name
St. Mary's Medical Park Pharmacy
Product Type
Human Prescription Drug
FDA Application #
NDA204790
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
08-13-2013
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 60760-748-07 identifies a specific commercial package of 7 tablet, film coated in 1 bottle, plastic of Tivicay, a human prescription drug labeled by St. Mary's Medical Park Pharmacy. This product is billed for "EA" each discreet unit and contains an estimated amount of 7 billable units per package. This tablet, film coated is formulated for oral use and contains dolutegravir sodium as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by St. Mary's Medical Park Pharmacy on August 13, 2013. The current certification is valid through December 31, 2027.

How is this St. Mary's Medical Park Pharmacy product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 60760074807. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 7 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
60760-748-07
11-Digit CMS (5-4-2)
60760-0748-07

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.